Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - Here's What Happened

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $21.67, but opened at $20.77. Dianthus Therapeutics shares last traded at $21.59, with a volume of 14,201 shares.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Wedbush reaffirmed an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Guggenheim restated a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $54.33.

Dianthus Therapeutics Stock Performance

The firm has a 50 day moving average price of $19.85 and a 200-day moving average price of $22.72. The firm has a market cap of $697.13 million, a price-to-earnings ratio of -8.68 and a beta of 1.62.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.33 million for the quarter, compared to analysts' expectations of $1.40 million. As a group, equities analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors have recently bought and sold shares of the business. TCG Crossover Management LLC acquired a new stake in Dianthus Therapeutics in the fourth quarter valued at approximately $32,735,000. Braidwell LP increased its stake in Dianthus Therapeutics by 144.4% during the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company's stock valued at $26,304,000 after purchasing an additional 712,902 shares during the last quarter. Vestal Point Capital LP grew its position in shares of Dianthus Therapeutics by 172.2% during the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock valued at $23,435,000 after buying an additional 680,000 shares during the last quarter. Octagon Capital Advisors LP lifted its holdings in shares of Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock worth $46,002,000 after purchasing an additional 363,500 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new stake in Dianthus Therapeutics in the fourth quarter valued at $3,924,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.